| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/10/2005 | US20050031583 Uses of opg to modulate immune responses |
| 02/10/2005 | US20050031579 Polymer encapsulation of adenoviruses |
| 02/10/2005 | DE10297513T5 In vitro Herstellung von dendritischen Zellen aus CD14+ Monocyten In vitro production of dendritic cells from CD14 + monocytes |
| 02/10/2005 | CA2536120A1 Polymer encapsulation of adenoviruses |
| 02/10/2005 | CA2534991A1 Short interfering rna as an antiviral agent for hepatitis c |
| 02/10/2005 | CA2534077A1 Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| 02/10/2005 | CA2531320A1 Reversibly immortalised olfactory ensheathing glia and their use to promote neuronal regeneration |
| 02/10/2005 | CA2529798A1 Methods of treating hepatocellular carcinoma with zvegf3 antagonists |
| 02/09/2005 | EP1505154A1 Vector with modified protease-dependent tropism |
| 02/09/2005 | EP1505153A1 Nucleic acid sequence comprising the rna packaging signal of a group 1 coronavirus and the applications thereof |
| 02/09/2005 | EP1504766A1 Drug- or gene-carrier composition having lowered hemagglutinin activity |
| 02/09/2005 | EP1504764A1 Treatment of liver fibrosis with antagonists of alpha V beta 6 integrin |
| 02/09/2005 | EP1504124A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions |
| 02/09/2005 | EP1504112A2 Development of a preventive vaccine for filovirus infection in primates |
| 02/09/2005 | EP1504108A2 Viral vector |
| 02/09/2005 | EP1504107A1 Recombinant fowlpox virus |
| 02/09/2005 | EP1504099A2 Novel nucleic acids and polypeptides |
| 02/09/2005 | EP1504098A2 A method for in vitro molecular evolution of protein function |
| 02/09/2005 | EP1504095A2 Site specific listeria integration vectors and methods for using the same |
| 02/09/2005 | EP1504026A2 Therapeutic polypeptides, nucleic acids encodings same, and methods of use |
| 02/09/2005 | EP1504016A2 Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses |
| 02/09/2005 | EP1503819A1 System and method for forming a non-ablative cardiac conduction block |
| 02/09/2005 | EP1503802A2 Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
| 02/09/2005 | EP1503801A2 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 02/09/2005 | EP1503793A2 Cancer vaccines and methods of using the same |
| 02/09/2005 | EP1503792A2 Attenuation of metapneumovirus |
| 02/09/2005 | EP1503785A2 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
| 02/09/2005 | EP1503716A1 System and method for treating cardiac arrhythmias with fibroblast cells |
| 02/09/2005 | EP1313885A4 Methods of using agents that modulate bone formation and inhibit adipogenesis |
| 02/09/2005 | EP1255850A4 AMPLIFICATION OF $i(CYP24) AND USES THEREOF |
| 02/09/2005 | EP1242112A4 Particulate drug-containing products and method of manufacture |
| 02/09/2005 | EP1030923B1 Method for producing virus-like particles on the basis of polyoma viruses |
| 02/09/2005 | EP1017805B1 Men1, the gene associated with multiple endocrine neoplasia type 1, menin polypeptides, and uses thereof |
| 02/09/2005 | CN1578840A Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes |
| 02/09/2005 | CN1578678A Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| 02/09/2005 | CN1578672A Rsv基因表达疫苗 Rsv gene expression vaccine |
| 02/09/2005 | CN1578647A Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
| 02/09/2005 | CN1576364A Building identification and application for heterogenic interbone marrow filling stem cell transplantation chimeric model |
| 02/09/2005 | CN1575819A Use of melanoma differentiation associated gene (mda-7) for reversing cancerous phenotype |
| 02/09/2005 | CN1575818A Genetic medicine for preventing or curing parkinson's disease, depression and treatment of giving up drugs |
| 02/09/2005 | CN1188528C Intercellular adhesion molecule-3 and its binding ligands |
| 02/08/2005 | US6852847 B7 nucleic acid molecules, proteins encoded by such nucleic acid molecules, antibodies raised against such proteins and inhibitors of such proteins or nucleic acid molecules |
| 02/08/2005 | US6852839 Fhm, a novel member of the TNF ligand supergene family |
| 02/08/2005 | US6852838 Nucleotide sequences coding polypeptide for use in the treatment of muscular disorders |
| 02/08/2005 | US6852837 Nucleotide sequences coding protein for use in the treatment nflammatory bowel disease, sepsis, viral diseases and rheumatoid arthritis |
| 02/08/2005 | US6852835 DNA molecules and polypeptides of Pseudomonas syringae Hrp pathogenicity island and their uses |
| 02/08/2005 | US6852755 This invention pertains to nitrogen mustard compounds (Formula (II)) and prodrugs therefor (Formula (I)), methods for their preparation, pharmaceutical compositions comprising such compounds, and the use of such compounds and |
| 02/08/2005 | US6852709 Biodegradable particles for use in time release agents and gene therapy |
| 02/08/2005 | US6852704 Compositions and methods for reverse gene therapy, wherein a gene therapy vector encoding a gene product (e.g. a protein) which is usually only expressed in cells of an abnormal tissue is delivered to a cell of an animal afflicted with a disease |
| 02/08/2005 | US6852703 A vector comprising a nucleotide sequence of interest ("NOI") encoding a product of interest ("POI") is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI |
| 02/08/2005 | US6852693 Compositions and methods for promoting lipid mobilization in humans |
| 02/08/2005 | US6852537 Transgenic circulating endothelial cells |
| 02/08/2005 | US6852535 A transcribed non-naturally occurring RNA molecule comprising a desired RNA molecule, wherein the 3' region of the RNA is able to base-pair with at least 8 bases at the 5' terminus of the same RNA molecule |
| 02/08/2005 | US6852533 For making vectors for gene therapy |
| 02/08/2005 | US6852530 Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same |
| 02/08/2005 | US6852528 Human and mouse uroplakin II gene transcriptional regulatory elements |
| 02/08/2005 | US6852520 DSP-2 dual-specificity phosphatase |
| 02/08/2005 | US6852518 Glycosyl sulfotransferases GST-4α, GST-4β, and GST-6 |
| 02/08/2005 | US6852515 For heparan sulfate binding extracellular domain; proteoglycans; in-situ; tumors/wound healing |
| 02/08/2005 | US6852509 Anti-P53 single-chain antibody fragments and their uses |
| 02/08/2005 | US6852334 Cationic peg-lipids and methods of use |
| 02/08/2005 | US6852323 Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder |
| 02/08/2005 | CA2180103C Gene encoding adseverin |
| 02/03/2005 | WO2005010189A1 OLIGONUCLEOTIDE INHIBITING THE EXPRESSION OF StAR-BINDING PROTEIN (SBP) GENE AND METHOD THEREFOR |
| 02/03/2005 | WO2005010185A1 Rna capable of inhibiting expression of klf5 gene |
| 02/03/2005 | WO2005010149A2 Subgroup b adenoviral vectors for treating disease |
| 02/03/2005 | WO2005009477A1 Compositions and methods for treating cardiac dysfunction |
| 02/03/2005 | WO2005009476A1 Intravascular delivery of non-viral nucleic acid |
| 02/03/2005 | WO2005009363A2 Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies |
| 02/03/2005 | WO2005009355A2 Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
| 02/03/2005 | WO2005009337A2 Treating severe acute respiratory syndrome |
| 02/03/2005 | WO2005009217A2 Diagnosis of pre-cancerous conditions using pcdgf agents |
| 02/03/2005 | WO2005009134A1 ACELLULAR TISSUE MATRICES MADE FROM GALACTOSE α-1,3-GALACTOSE-DEFICIENT TISSUE |
| 02/03/2005 | WO2005000335A3 Use of genes differentially expressed during aging of liver for treatment and diagnosis |
| 02/03/2005 | WO2004102195A8 Method for identifying tff2 regulating agents and agents identified using said method |
| 02/03/2005 | WO2004076639A3 Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus |
| 02/03/2005 | WO2004070018A3 Vegf-b and pdgf modulation of stem cells |
| 02/03/2005 | WO2004047872A3 Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) |
| 02/03/2005 | WO2004045527A3 Modulation of nima-related kinase 6 expression |
| 02/03/2005 | WO2004043990A3 Human stem cell materials and methods |
| 02/03/2005 | WO2004002416A3 Methods and materials for treating human papillomavirus infections |
| 02/03/2005 | WO2003099850A3 Mutant p53 (δ126-132) protein and uses thereof |
| 02/03/2005 | WO2003096988A3 Tr4/tr2 response elements |
| 02/03/2005 | WO2003094859A3 Epha2 monoclonal antibodies and methods of use thereof |
| 02/03/2005 | WO2003089613A3 Tocopherol associated protein and uses thereof |
| 02/03/2005 | WO2003081250A8 Novel compositions and methods in cancer associated with altered expression of prlr |
| 02/03/2005 | WO2003079967A3 Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue |
| 02/03/2005 | WO2003062390A3 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
| 02/03/2005 | WO2003040317A8 Lung cancer therapeutics and diagnostics |
| 02/03/2005 | WO2003039342A3 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145 |
| 02/03/2005 | US20050028228 Acellular tissue matrices made from alpa-1,3-galactose-deficient tissue |
| 02/03/2005 | US20050027114 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 02/03/2005 | US20050027064 Charge-dynamic polymers and delivery of anionic compounds |
| 02/03/2005 | US20050026863 Delivery of therapeutic gene products by intestinal cell expression |
| 02/03/2005 | US20050026861 Modified dinucleotides for reduce or improve immunostimulatory; genetic vaccines; cancer vaccines |
| 02/03/2005 | US20050026860 Nucleolin antisense sequence for inhibition of cancer cell proliferation |
| 02/03/2005 | US20050026859 Methods and compositions of gene delivery agents for systemic and local therapy |
| 02/03/2005 | US20050026841 Hab18g/cd147 its antagonist and application |
| 02/03/2005 | US20050026838 Fibroblast Growth Factor-13 |
| 02/03/2005 | US20050026832 Expression vector comprising nucleotide sequences coding fibroblast growth for use in generating transgenic animal model for use in treatment and prevention of eating disorders and obesity |